Opiant Pharmaceuticals, Inc. (OPNT)
Market Cap | 108.80M |
Revenue (ttm) | 22.34M |
Net Income (ttm) | -33.09M |
Shares Out | 5.27M |
EPS (ttm) | -6.57 |
PE Ratio | n/a |
Forward PE | 26.74 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 492,256 |
Open | 20.88 |
Previous Close | 20.65 |
Day's Range | 20.50 - 21.00 |
52-Week Range | 7.34 - 29.25 |
Beta | 0.83 |
Analysts | Sell |
Price Target | 21.93 (+6.2%) |
Earnings Date | Mar 21, 2023 |
About OPNT
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorpo... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for OPNT stock is "Sell." The 12-month stock price forecast is $21.93, which is an increase of 6.20% from the latest price.
News

Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.
Combination Strengthens Indivior's Addiction Treatment and Science Portfolio RICHMOND, Va. , March 2, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) ("Indivior" or the "Company") today announced that i...

Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the pr...

Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino...

Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals
Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals.

Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ...

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook
- Peak Annual Net Revenue Potential for SUBLOCADE ® Increased to > $1.5 Billion - Attractive and Scalable Business Outlined – Expects Strong Net Revenue Growth and Operating Margin Expansion Over the...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, OPNT, BNFT, ABMD
NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose
SANTA MONICA, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has completed submission of its rolling New Drug Application (NDA) to ...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Opiant Pharmaceuticals, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - November 21, 2022) - Rigrodsky Law, P.A. is investigating Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT) regarding possible breaches of fiduciary duties...

EQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNT
NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm ra...

OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. - OPNT
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Opiant Pharmac...

SHAREHOLDER ALERT: Weiss Law Investigates Opiant Pharmaceuticals, Inc.
NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Opiant Pharmaceuticals, Inc. ("Opiant" ...

Why Is Opiant Pharma (OPNT) Stock Up 116% Today?
Opiant Pharmaceuticals (NASDAQ: OPNT) stock is rocketing higher on Monday following news that Indivior is acquiring the Narcan maker! Indivior is offering to acquire shares of OPNT stock for $28 each...

OPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) to Indivior PLC is fair to Opiant sharehold...

Shareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with Indivior
MILWAUKEE , Nov. 14, 2022 /PRNewswire/ -- Ademi LLP is investigating Opiant (NASDAQ: OPNT) for possible breaches of fiduciary duty and other violations of law in its transaction with Indivior. Click ...

Opiant, maker of Narcan, to be acquired in $145 million deal
Shares of Opiant Pharmaceuticals Inc. OPNT, +1.06% soared 120.8% in premarket trading on Monday after the company, which is best known for selling the opioid overdose treatment Narcan, said it will be...

Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
SANTA MONICA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug ove...

Indivior PLC to Acquire Opiant Pharmaceuticals
SANTA MONICA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) today announced that it has entered into a definitive merger agreement to be acquired by Indivior Inc...

Indivior To Acquire Opiant Pharmaceuticals
Acquisition Strengthens and Extends Indivior's Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristic...

Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions...

Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder
SANTA MONICA, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overd...

Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome
SANTA MONICA, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced that the United States Patent and Trademark Office (USPTO) has issued a Not...

MindMed Strengthens Board with Appointment of Two New Independent Directors
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain h...

Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug ove...

Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene
SANTA MONICA, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the Biomedical Advanced Research and Development Authority (BARDA) h...